TAAR1 agonists did not appear to differ from placebo in adverse events in participants with psychosis at 4–6 weeks, including for serious adverse events, nausea/vomiting, QTc prolongation, weight increase, prolactin elevation, akathisia, extrapyramidal side-effects, sedation and insomnia, with absolute frequencies generally not exceeding 5% (Figure 3). This evidence concerns the gene PRL and psychotic disorder.